Breast cancer screening programs are the best way to catch breast cancer early, the number one cause of woman death in the US, but these programs are in danger. The volumes of images to review are increasing, the experts are scarce and the costs for detection and treatment are tremendously high ($38 billion in the US . MammoScreen is a solution that helps radiologists to read mammograms faster and more accurately, increasing the efficiency of the readings, and helping them to detect cancer earlier, thus reducing treatment costs. MammoScreen is FDA cleared and CE mark for assisting radiologists with the review of 2D and 3D mammograms and associated prior exams. 

Breast cancer screening programs are the best way to catch breast cancer early, the number one cause of woman death in the US, but these programs are in danger. The volumes of images to review are increasing, the experts are scarce and the costs for detection and treatment are tremendously high ($38 billion in the US . MammoScreen is a solution that helps radiologists to read mammograms faster and more accurately, increasing the efficiency of the readings, and helping them to detect cancer earlier, thus reducing treatment costs. MammoScreen is FDA cleared and CE mark for assisting radiologists with the review of 2D and 3D mammograms and associated prior exams. 

With this program, we had the ability to connect with many stakeholders from the Mayo Clinic and ASU, to start building a strong relationship for the clinical use of our existing product and potential co-development of other solutions in the field of women's health. We also had the opportunity to better understand the payer system and build strategies to get reimbursement of our existing and future products.

"Learning has been invaluable. We came with questions and uncertainties and leave with a clear plan to resolve them at many levels."

Matthieu Leclerc-Chalvet
CEO